User Profile
Select your user profile

cobas® Cdiff

Nucleic acid test for use on the cobas® liat system

IVD For in vitro diagnostic use.
<b>cobas</b><sup>®</sup> Cdiff

See C. diff sooner, start patient care faster

The cobas® Cdiff is a real-time PCR test that provides accurate, on-demand results in 20 minutes for the detection of toxigenic C. diff in unformed stool specimens from patients suspected of having a C. diff infection (CDI).

cobas® Cdiff
  • Empowering faster informed isolation precautions with results in just 20 minutes
  • Reducing the risk of missing an acute infection with enhanced toxigenic C. diff strain coverage
  • Expanding C. diff testing beyond the lab with complete cobas® liat system connectivity

 

The cobas® liat system enables definitive and rapid diagnosis, combining powerful PCR technology with fast turnaround time, 20 minutes or less, allowing sample to answer while patients wait.

cobas® Cdiff performance

View Full Table

cobas® Cdiff performance

  Sensitivity* Specificity*
Cdiff
LOD: 45-90 CFU/swab
93.5 %
(95% CI: 88.1% - 96.5%)
96.4 %
(95% CI: 94.6% - 97.7%)
*Compared to direct culture. CI=confidence intervals. CFU=colony forming units.
cobas® liat system

cobas® liat system

Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.

Traditional testing methods vs. cobas® liat system

Traditional diagnostic methods are either time-consuming, labor-intensive or inaccurate when used alone. Testing algorithms have been developed to overcome the shortcomings of individual methods. However, these algorithms are complex and can introduce delays in result reporting, which may adversely impact patient management.

Traditional testing
methods
chart_col_A_1_CDIFF

Patient with CDI symptoms

chart_col_A_2_CDIFF

Isolate

chart_col_A_3_CDIFF

Collect sample and send to lab

chart_col_A_4_CDIFF

Process with lab PCR or algo EIA

chart_col_A_5_CDIFF

Positive results: initiate antibiotics
Negative results: admit patient without
isolation and search for symptom etiologies

cobas® Cdiff
test
chart_col_C_1_CDIFF

Patient with CDI symptoms

chart_col_A_3_CDIFF

Collect sample and send to lab

chart_col_C_3_CDIFF

The cobas® liat system provides
accurate results in only 20 minutes

chart_col_C_4_CDIFF

Positive results: isolate and initiate antibiotics
Negative results:, admit patient without
isolation and search for symptom etiologies

See C. diff sooner with cobas® Cdiff to transform your patient care pathway.

Relying on the fast, accurate results from cobas® Cdiff, healthcare professionals are now able to streamline CDI diagnosis to reduce unnecessary isolation, empiric use of antibiotics and to initiate appropriate infection control measures.

Intended Use

The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is an automated, qualitative in vitro diagnostic test that uses real-time polymerase chain reaction (PCR) for the detection of the toxin B (tcdB) gene of toxigenic Clostridioides difficile in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.


The cobas® liat system is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Registration status

CE-IVD, FDA 510(K) cleared

 

The cobas® liat system is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Package inserts

Access package inserts through your country’s Roche Diagnostics Website.

References

  1. https://cdifffoundation.org/2014/11/24/c-difficile-infection-cdi-european-clinician-consensus-report-with-recommendations-for-improved-management-of-cdi, accessed on Nov, 2023.
  2. Gupta A, et. al. Extraintestinal Clostridium difficile infections: a single-center experience. Mayo Clin Proc. 2014 Nov;89(11):1525-36. doi: 10.1016/j.mayocp.2014.07.012. Epub 2014 Sep 20. PMID: 25245597.
  3. cobas® Cdiff [package insert v4], Pleasanton, CA; Roche Molecular Systems, Inc., 2022

COBAS and LIAT are trademarks of Roche.

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

...
    ...

    Technical Documents

    Access important product documentation including relevant certificates and other resources.

    After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.